Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...

Voyager Technologies awarded follow-on contract under NASA ELVIS 3 program

Voyager Technologies (VOYG) was awarded a follow-on contract under NASA’s Expendable Launch Vehicle Integrated Support 3, or ELVIS 3, program through prime contractor a.i. solutions. The multi-million ...

Voyager Awarded Multi-Million-Dollar NASA Contract

Voyager Technologies (NYSE: VOYG) was awarded a follow-on contract under NASA’s Expendable Launch Vehicle Integrated Support 3, or ELVIS 3, program through prime contractor a.i. solutions. The ...
Fierce Biotech

Voyager pauses Alzheimer's program just 8 months after unveiling asset

Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...